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Abstract
Background: Despite the promising benefits of adaptive designs (ADs), their routine use, especially in confirmatory
trials, is lagging behind the prominence given to them in the statistical literature. Much of the previous research to
understand barriers and potential facilitators to the use of ADs has been driven from a pharmaceutical drug
development perspective, with little focus on trials in the public sector. In this paper, we explore key stakeholders’
experiences, perceptions and views on barriers and facilitators to the use of ADs in publicly funded confirmatory trials.
Methods: Semi-structured, in-depth interviews of key stakeholders in clinical trials research (CTU directors, funding
board and panel members, statisticians, regulators, chief investigators, data monitoring committee members and
health economists) were conducted through telephone or face-to-face sessions, predominantly in the UK. We
purposively selected participants sequentially to optimise maximum variation in views and experiences. We employed
the framework approach to analyse the qualitative data.
Results: We interviewed 27 participants. We found some of the perceived barriers to be: lack of knowledge and
experience coupled with paucity of case studies, lack of applied training, degree of reluctance to use ADs, lack of
bridge funding and time to support design work, lack of statistical expertise, some anxiety about the impact of early
trial stopping on researchers’ employment contracts, lack of understanding of acceptable scope of ADs and when ADs
are appropriate, and statistical and practical complexities. Reluctance to use ADs seemed to be influenced by:
therapeutic area, unfamiliarity, concerns about their robustness in decision-making and acceptability of findings to
change practice, perceived complexities and proposed type of AD, among others.
Conclusions: There are still considerable multifaceted, individual and organisational obstacles to be addressed to
improve uptake, and successful implementation of ADs when appropriate. Nevertheless, inferred positive change in
attitudes and receptiveness towards the appropriate use of ADs by public funders are supportive and are a stepping
stone for the future utilisation of ADs by researchers.
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Background
Traditionally, standard randomised controlled trials
(RCTs) are designed with a fixed target sample size and
recruit until this target is met. Recently, much attention
has been paid to alternative types of RCTs, known as
adaptive designs (ADs), in which prospectively planned
modifications to the design are made based on accruing
outcome data from an ongoing trial while preserving the
scientific validity and integrity of that trial [1, 2]. This may
mitigate the risk of making inaccurate design assumptions
or potentially may shorten trial duration by allowing early
stopping as soon as there is sufficient evidence to answer
the research question(s) [2]. However, despite potential
promising benefits to clinical trials, patients and funders,
the use of ADs in practice, particularly in the public sector,
has been described by advocates as disappointing - with
their uptake lagging far behind methodological develop-
ments [3]. Moreover, the use of ADs is viewed as contro-
versial, with the perception among some stakeholders that
public funders and regulators have hindered their wider
adoption [4].
Citing disappointing uptake, the pharmaceutical indus-
try initiated a Pharmaceutical Research and Manufac-
turers of America (PhRMA) Adaptive Design Working
Group with a vision to facilitate dialogue among key
stakeholders in drug development and to establish a
consensus position on the use of ADs [5]. The group
further investigated barriers and opportunities associated
with the use of ADs across different trial phases, specif-
ically in drug development. Although much related dis-
cussion and research has subsequently been undertaken
[2, 5–10], it has been led and driven by the pharmaceut-
ical industry, especially in the USA, with the public sec-
tor lagging behind.
Researchers have highlighted that the public sector has
its own unique multifaceted challenges, which need to
be explored in detail and addressed in order to improve
uptake of ADs [2, 11, 12]. With this in mind, the NIH
(National Institutes of Health, USA) and associates
funded and facilitated a 2-day workshop to initiate some
cross-industry discussions with representatives from the
NIH, the Food and Drug Administration (FDA), the
European Medicines Agency (EMA), the pharmaceutical
industry, non-profit foundations, patient representatives
and academia [12]. Some recommendations have since
been drawn up to enhance the use of ADs [11, 12].
Although this has been a significant milestone, the NIH
workshop did not explore the perceptions and attitudes
towards ADs of key stakeholders directly involved in the
day-to-day conduct of clinical trials. Furthermore, some
of the NIH findings may not be directly extrapolated to
the UK setting, due to differences such as public funding
and clinical trials infrastructure, capacity issues and
underlying perceptions.
Little research has been undertaken to explore the use
of ADs in the publicly funded confirmatory setting, par-
ticularly in the UK. In 2012, Morgan and colleagues [3]
investigated the use of ADs and associated perceptions
of barriers in the private and academic sector through a
survey. The authors found change management, regula-
tory acceptance, lack of education and extra time and
resources required for planning as major perceived bar-
riers. Jaki [13] also investigated the use of ADs and
Bayesian methods in early phase trials through a cross-
sectional survey of registered UK Clinical Trials Units
(CTUs), predominantly surveying statisticians. The poor
application of these methods was attributed to five key
barriers: lack of software, clinical investigators insisting
on preferred methods, lack of expertise, inadequate
funding structure and time required for trial design.
These researches demonstrated the existence of barriers
impeding the use of ADs. We have endeavoured to fill
the gap in previous research [2, 3, 8, 9, 11–14] by
incorporating nested qualitative interviews of key stake-
holders with diverse roles in clinical trials research with
a focus on publicly funded confirmatory trials prior to
subsequent related surveys to be reported elsewhere.
This study is motivated by the belief that further related
research and discussions are needed in the UK publicly
funded confirmatory setting. Understanding perceptions
towards ADs by researchers and decision-makers is key to
unlocking potential benefits of ADs in this setting. We
therefore aimed to explore key stakeholders’ experiences,
perceptions and attitudes towards ADs in publicly funded
confirmatory trials and their views on barriers and facilita-
tors to the use of ADs. We believe our findings will inform
researchers and decision-makers on key issues, in order to
facilitate their preparedness to utilise acceptable ADs in
publicly funded confirmatory trials where appropriate.
Methods
Study design and setting
This study valued the importance of understanding obsta-
cles to AD use from the point of view of key stakeholders’
experiences, perceptions and attitudes, in order to gener-
ate facilitators to unlock barriers to appropriate use. This
approach, which explores views, meaning and context, can
be viewed within the phenomenological paradigm [15].
Hence, we conducted cross-sectional, in-depth, semi-
structured, one-to-one qualitative interviews of key stake-
holders involved in clinical trials research [16]. This
approach encouraged participants to talk about pertinent
issues about ADs through the use of open-ended ques-
tions. Some of these questions were a priori-designed
based on topics from previous literature [7–9, 11, 14], and
others were informed by researcher-driven hypotheses.
Although we paid attention to the UK publicly funded set-
ting, a cross-sector approach was undertaken by including
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participants with private sector experiences in order to
explore diverse experiences, perceptions and attitudes. In
particular, we purposively sought expertise in the private
sector due to a perceived greater experience of ADs [2]. In
addition, four international participants were included in
our sample in response to advice given by some partici-
pants during the interviews. We conducted interviews by
telephone or through face-to-face conversations based on
feasibility and the need to reach out to a wider geograph-
ical area of participants of interest.
Sample size
Most qualitative studies base their sample size on reaching
data saturation, which is unknown in advance because it
depends on various factors such as: the scope and nature
of the research subject, study design and resources avail-
able [17–20]. Some authors recommend up to 10 homo-
geneous interviews for phenomenological research [19].
Bearing this and time constraints in mind, we intended to
recruit six to eight participants per expertise category,
yielding a minimum of 20 participants depending on the
degree of overlap in expertise. We also adapted our sam-
pling in some expertise categories guided by richness of
information from previous interviews and the need for
further exploration of certain phenomena. Overlapping of
participant roles afforded an opportunity to explore wider
views and experiences with a smaller sample.
Selection of participants
We purposively selected participants in a consecutive
manner following informed consent agreement if they met
the desired core duties and responsibilities in trials re-
search. We adopted this cross-disciplinary approach to
optimise maximum variation to capture diverse views and
experiences [21]. Core expertise for purposive sampling
were UK CTU leaders (directors or deputy directors),
public funding panel and board members (chairs or vice
chairs including other ordinary members), Independent
Data Monitoring Committee (IDMC) members, regula-
tors, statisticians, health economists and chief investiga-
tors. We sent an invitation letter with an information
sheet to target participants using various platforms; mass
emailing to specialist network groups including the UK
CRC Registered CTU Network [22] and the MRC Net-
work of Hubs for Trial Methodology Research [23]; and
personalised emails to referred contacts and hard to reach
groups, such as private sector, regulators and public fund-
ing panel and board members.
We phrased the invitation letter to emphasise that par-
ticipants would be eligible to participate regardless of
their underlying experiences, perceptions and attitudes
towards ADs in order to minimise potential responder
bias due to oversampling of participants likely to express
positive views. We asked responders to complete a short
questionnaire detailing their demographic characteristics
and key expertise and to return it with their signed
informed consent form. We then sequentially selected
participants until reaching the desired target sample size.
We used interview guides tailored for participants’ expert-
ise to prompt questions (see Additional file 1). We under-
took five internal pilot interviews, four of which were
face-to-face to test the appropriateness of the interview
guides, prompts and interview duration. On completion
of the interviews, we gave participants an option to verify
their interview transcript and also to say anything relevant
about ADs that they felt was not covered but worth
contributing.
The lead author (MD) conducted the interviews, which
were audio recorded and verbatim transcribed by experi-
enced in-house transcribers. A favourable ethical opinion
(0676) was received from the Research Ethics Committee
of the School of Health and Related Research at the
University of Sheffield, and all interviews were conducted
with signed informed consent.
Analysis and reporting
Data were entered into NVivo10 [24], which was used to
manage and organise the data analysis process. We
employed the framework method [25, 26] to structure the
analytical process, which includes the following key stages;
familiarisation and annotation of transcripts, identifying a
thematic framework [27], indexing, charting, mapping,
and interpretation [28–30]. Mapping helped to identify
relationships and clusters around themes, thereby facilitat-
ing understanding, communication and interpretation.
Themes captured what is most important from the data in
understanding views and experiences concerning the use
of ADs. We adapted taxonomies developed and used by
other authors in the field of evidence-based practice to
classify barriers to the uptake of ADs into micro- and
macro-level domains pertinent to key stakeholders at the
individual and organisational level [31–33]. Some poten-
tial facilitators to perceived barriers are also presented.
We paid attention to emerging themes and contrasted
these with the existing literature. Supplementary inter-
view data and case studies to support themes are pro-
vided (see Additional file 2). We utilised the COREQ
checklist to guide the conduct, analysis and reporting
of this study [34].
Results
Description of participants
In total, 27 participants were interviewed between March
and August 2014, predominantly based on a sampling
frame of 45 registered UK CTUs (2012/2013). Previous
AD experience of participants is shown in Table 1. One
health economist agreed to be interviewed. Reasons for
not taking part among 17 health economists who were
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directly invited were unfamiliarity with ADs (n = 5), busy
schedule (n = 1), non-response (n = 10) and willing but
incompatible schedule (n = 1).
Interviews were conducted by telephone (n = 17), face-
to-face (n = 7), skype video call (n = 2) and skype tele-
phone call (n = 1). Median duration (IQR) of interviews
was 31 (26 to 38) minutes ranging from 13 to 51. Partici-
pants’ characteristics, demographics and diverse overlap-
ping primary duties and responsibilities in clinical trials
research are displayed in Tables 1 and 2.
Perceived value of ADs and opportunity for use in
confirmatory trials
Perceived advantages of ADs
Participants stated potential advantages of ADs, which can
be broadly classified into three categories: ethical benefits
to patients, improving design efficiency to answer research
question(s), and value for money. These perceived advan-
tages are summarised with supporting data in Table 3 and
Additional file 2.
Perceived therapeutic areas of opportunity to use ADs
In principle, most participants acknowledged that ADs
could be applicable across a wide spectrum of thera-
peutic areas (see Additional file 2). However, some par-
ticipants also believed ADs may be more appealing or
appropriate for certain health conditions or populations,
due to factors such as severity of the health condition,
availability of standard care options and limitations of
standard methods (such as in small populations).
Some participants mentioned the potential value of ADs
in areas including, but not limited to oncology; emergency
medicine; and respiratory, cardiovascular, infectious and
rare or orphan diseases. Participants stated that the nature
of the clinical outcome(s) of interest and study interven-
tion may also influence relevance of ADs. A case study
was shared on how ADs could be of value in evaluating
interventions during outbreaks of rapidly evolving and
fatal pandemics such as influenza or Ebola, due to the se-
verity of the conditions, coupled with the need for urgent
clinical decision-making by policymakers (see Additional
file 2, Case Study A). Most importantly, participants stated
that it is imperative that the proposed AD is fit for the
purpose of robustly answering the research question(s)
accompanied by a clear rationale.
Perceived types of ADs with potential in confirmatory
setting
Participants mentioned that the following types of ADs
have useful potential within the confirmatory setting,
which are also reflected in the literature [1, 2, 8, 9, 35–38].
However, the receptiveness towards these ADs by the
research community and policymakers varied considerably
depending, for instance, on the type and scope of the
adaptation. These types include the following:
1. Sample size re-estimation (SSR) conducted either in
a blinded or unblinded manner.
2. Futility assessment based on stochastic curtailment
(such as conditional power)
3. Standard group sequential design (GSD) allowing for
early stopping (such as for futility and/or safety and/
or efficacy and/or non-inferiority).
4. Strictly phase 3 multi-arm multi-stage design
(MAMS) with treatment selection allowing for
dropping of inferior or futile treatments and/or early
trial stopping.
5. Operational or inferential seamless 2/3 design with
treatment selection in phase 2.
6. Response adaptive randomisation (strictly based on
primary outcome data).
Table 1 Characteristics and demographics of interviewed
participants
Variable Scoring Total
(N = 27)
Sex Male 17(63 %)
Female 10(37 %)
Age group (years) >30 to 35 4(15 %)
>35 to 40 2(7 %)
>40 to 45 8(30 %)
>45 to 50 4(15 %)
>50 to 55 4(15 %)
>55 5(19 %)
Academic qualifications MSc/MA or equivalent 3(11 %)
PhD/DPhil/DSc or equivalent 21(78 %)
Other 3(11 %)
Trials experience (years) 0 to 2 1(4 %)
>2 to 5 1(4 %)
>5 to 10 2(7 %)
>10 to 15 6(22 %)
>15 17(63 %)
Current employment sector Private 4(15 %)
Publica 22(81 %)
Both private and public 1(4 %)
Mode of interview Face-to-face 7(26 %)
Telephone 17(63 %)
Skype telephone call 1(4 %)
Skype video call 2(7 %)
Location UK 23(85 %)
International 4(15 %)
aSix participants had previous private sector experiences. Participants’ diverse
previous AD experiences: none (n = 9), of which six expressed interest in ADs;
during planning only (n = 6); during planning and conduct, either in early or
confirmatory phase or both (n = 8); statistical regulatory assessment (n = 4)
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Public funders’ perceived change in attitudes towards ADs
We inferred a paradigm shift in attitudes towards ADs by
public funders, mainly motivated by value for money and
the desire to make use of the public purse more efficiently.
Funders expressed a clear positive will and receptiveness
to fund adaptive trials and to encourage researchers to
utilise ADs, whenever appropriate, to answer the research
question(s). This view, supported by various initiatives
relating to ADs funding opportunities (such as training
fellowships and grant calls) [39–41], was acknowledged
and welcomed by researchers.
‘I think generally speaking we are receptive
to those ideas (of ADs) and in fact we, at
[organisation] have held our own workshops on
ADs last year or the year before in order to try
and promote more use of ADs providing they are
appropriate of course. So I think 10 years ago our
attitudes were more towards traditional parallel
group, it was a sort of traditional well-known pathway
but I think now our modern thinking is that we
welcome ADs when appropriate and it is very much
for the applicants to make the case for why they want
maybe four arms with interim analyses for dropping
arms …’ (QL35 Chair - Public Funder)
Regulatory receptiveness and improving awareness
and experiences
In principle, there appeared to be regulatory recep-
tiveness towards the concept of ADs, but this was
conditional on strong caveats, particularly in con-
firmatory trials on measures such as minimisation of
operational bias during the conduct to preserve trial
credibility and integrity, control of type I error, and
use of appropriate statistical inference. These caveats
and considerations are highlighted in regulatory guid-
ance and reflection papers specific to drugs and bio-
logics [42–44]. We inferred that regulatory awareness
and experience is growing, particularly among statis-
tical assessors due to the increasing number of AD-
related scientific advice consultations and applications
by researchers; especially on SSR, futility assessment
and GSD trials, as also reflected in recent literature
[14, 45].
‘I haven’t got the figures in front of me and I
wouldn’t know how to get them but you see a lot
more of them at the moment in the scientific
advice arena, when people are coming saying ‘this
is what we are going to do, what do you think?’ …
I get a lot of them starting and not so many of
them finished yet’. (QL19 Regulator, regulatory
assessment experience)
Regulators advised researchers to engage them
through scientific advice meetings and to adhere to their
guidance when considering appropriate ADs from trial
planning to the end.
Cross-disciplinary interest and positive clinical will
Most participants expressed widespread growing inter-
est towards ADs even through there are existing
concerns.
‘I guess there are a lot of concerns about them and so
that’s perhaps why they’re not taken up so much. But it
Table 2 Overlap of core duties and responsibilities of 27 participants in clinical trials research
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Statisticians 10 6 0 0 3 1 6 5 4 
a 7 0
Co-applicants on grants 14 5 1 4 4 10 10 1 10 0
Chief investigators 8 2 1 2 4 4 0 2 0
Panel chairs (public funder) 3 0 0 0 1 0 0 0
Other panel members (public 
funder)
5 1 4 3 0 4 0
CTU directors/deputy directors 5 3 4 0 3 0
IDMC members 10 8 0 8 0
TSC members 10 0 8 0
Regulators 4 1 0
Trial methodologists 12 0
Health economists b 1
a Duties and responsibilities during the interview fit in with statistical regulatory assessments although not indicated as statisticians on the baseline form
b Member of a national health economics appraisal board
Interpretation: For instance (row 1), we interviewed 10 Statisticians with other overlapping roles: six had been co-applicants on research grants, three served on
public funding boards or panels, one served as a UK CTU leader, six were IDMC and five TSC members, and so forth
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is interesting to see that there’s a lot more interest in the
past few years and so maybe that is changing’. (QL26
Statistician, design and conduct experience)
‘… influential bodies like the FDA are now embracing
ADs and there is probably an increasing number of
ADs that are being utilised and will come through
and report over the next 2/3/4 years …’ (QL21 Chief
Investigator, design experience)
We also inferred a positive will by clinical investigators
contradicting previous related findings in early phase trials,
suggesting that clinical investigators insist on application of
certain methods [13].
Table 3 Characterisation of potential benefits to patients, clinical trials and funders
Thematic area Characterisation of potential benefits Some supporting quotations
Ethics: patient benefit Early stopping of trials as soon as there is sufficient
evidence to answer the research question(s) means:
‘It really depends on the type of AD so if you
have a GSD (Group Sequential Design) then
of course you can stop early for futility or
overwhelming effect and this clearly has many
ethical and financial advantages. So for futility
stopping –if it doesn’t work you can stop early
on and the patients don’t get exposed to a drug
that does not work or if you have overwhelming
effect that is also very positive you can move on
with the development of your drug and you don’t
have to finish the whole trial’. (QL11 Statistician)
▪ Minimisation of unnecessary over recruitment of
research patients
▪ Acceleration of the evaluation of interventions,
approval and commissioning into practice.
Thus, patients receive effective interventions quicker
‘…from a patient point of view the sooner that if
there is a new intervention that is really effective
then we want to get that into NHS (National Health
Service) practice, equally if it is dangerous or if there
is anything that we shouldn’t be using then we would
want to get that out and into guidelines and NHS
practice as much as possible’. (QL01 CTU Deputy
Director, Proposal Developer)
▪ Minimisation of the exposure of patients to
potentially ineffective and/or unsafe interventions
▪ Patients are likely to be allocated to interventions
to which they have a higher chance to respond
better; vital in critically ill patients
‘When you certainly have a limited patient pool like
orphan disease implications where you know you’re
not going to be able to actually recruit sufficient
patients for a full Phase 2/3 traditional development
programme and we accept and understand that, as
regulators and industry, you’re offered appropriate
incentives under orphan designation in the EU
(European Union) and US (United States). So, there’s
undoubtedly a challenge - an opportunity to maximise
the best use of patients. I've once actually seen a
combined Phase 1/2/3 study, all in one go’.
(QL16 Regulator)
▪ Identification of group of patients who are most
likely to respond to the intervention [61, 62]
Efficiency in trial design ▪ Mitigating the risk of making wrong design
assumptions
‘One of the things that I always tend to tell people
is that ADs will make you address the objectives
of interest enabling you to make the right decisions
earlier rather than later, for example, the biggest
opportunity is stopping poor drugs early, most of
our drugs fail, 90 % of the drugs that we start
developing in phase 1 never get to the full registration,
we should be killing those drugs as early as possible
and ADs allow you to do that, whether it is in phase
2 or 3 there is always that opportunity to stop early
for futility’. (QL15 Statistician)
▪ Allows simultaneous testing of multiple
interventions from a competing list with
option for dropping inferior interventions
in a single trial rather than multiple
series of two-arm trials [46]
▪ Allows the answering of research questions
quicker to expedite decision making
‘The main advantages of ADs accrue to funders because
funders are not paying for essentially redundant data
and ethically I think there is a benefit to patients because
clearly we don’t want to be recruiting patients to trials
when there is no significant potential of that trial and
additional data giving you any new information’. (QL04
Chief Investigator, Vice Chair - Public Funder)
▪ Efficient use of a limited patient pool, particularly
in rare or orphan disease implications
▪ Efficient use of a finite pool of clinical chief
investigators
Value for money for
funders/sponsors
▪ Avoiding pursuing the lost cause when trials are
stopped early for futility
▪ Efficient use of available research resources.
Stopping trials early means resources are
reallocated to other promising or
priority areas
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‘We definitely have an interest in advancing new
methods in the field of sepsis and in particular
there is probably room for improving clinical trial
design and that is the focus of our group (ADs
methods)’. (QL22 Chief Investigator, design
experience)
Most importantly, the positive desire expressed by
clinical investigators appears to depend mostly on how
trialists market ADs to them and the availability of sup-
port during trial planning and conduct.
‘I think generally once you have explained it (AD
concept), and you have said that it will be a very big
expensive trial if we did it fully powered for as long as
it would take, but say that it can be broken down to
give different options to the funder for shorter time
periods, and less cost, then they can see the
advantages to it. … if we are happy to do it and design
it and write that section up for them they will take it
on’. (QL01 CTU Deputy Director, Proposal Developer,
design experience)
‘Sometimes you need to sell it to them to get them to
see its positives and advantages and in terms of the
extra complication it takes to implement them’.
(QL07 Statistician, design and conduct experience)
Cross-disciplinary interest appears to be influenced by
the desire to improve design efficiency to answer clinical
research questions, address ethical aspects and maximise
value for money in research (Table 3).
‘… (ADs) makes a lot of sense from my point of
view and in terms of optimising the design and
feasibility of the study to address the particular
research question. I think it is important that
statisticians and clinicians discuss thoroughly the
options that are available in clinical trial design to
agree the best proposal because each will have
particular insights with regard to how to address a
research question and so communication is really
essential’. (QL24 Chief Investigator, design
experience)
‘…there is a lot of interest in them from a funder’s
point of view, in that particularly difficulties in
recruitment, when it has taken a long time to
recruit for trials when recruitment is not up to its
expected levels, it is very helpful to be able to have
a design that allows you to have multiple looks at
the data and to potentially stop early’. (QL04 Chief
Investigator, Vice Chair - Public Funder, design
experience)
Perceived potential barriers to the use of ADs in
confirmatory trials
Cross-disciplinary lack of awareness and understanding
Some participants viewed the widespread lack of aware-
ness and understanding of different types of ADs, circum-
stances when ADs are appropriate, and implementation
resources, as barriers to appropriate use. Consequently,
some participants believed that there are missed oppor-
tunities and underutilisation of ADs when appropriate in
some trials. Some expressed worry that misunderstanding
of when ADs are appropriate may lead to misuse, due to
their growing prominence - even in certain circumstances
when ADs are not superior to traditional fixed sample size
designs.
Confusion over what is meant by an AD
One resonant finding we inferred is the potential for
misunderstanding of what is meant by the term AD and
its acceptable scope in the confirmatory phase. Most
participants acknowledged a broadening of the scope of
what is considered to be an AD in recent years. Conse-
quently, the term is often loosely defined, but with broad
contextual meaning prone to misinterpretation leading
to confusion among researchers.
‘I would say, over the last three years, I’ve become
aware of (the) detail of ADs. Prior to that, it was a
sort of loosely bandied term … I could be in a room
and everybody thinks they’re talking about the same
thing and they’re talking about very different things’.
(QL8 CTU Director, no experience)
‘So I am generally in favour (of ADs); however,
convincing the community of that takes some work,
so a big threat for ADs is just that it’s a cutesy word
that means different things to different people, there’s
misinformation about it and there are some existing
biases in the community and so there really needs to
be a lot of education’. (QL22 Chief Investigator,
design experience)
Although this confusion has been partly addressed from
a regulatory and industry perspective [8, 42, 43], some
participants viewed it as a current problem in the public
sector, where most study interventions do not require
regulatory approval beyond standard ethics.
Cross-disciplinary conservatism
Most participants viewed cross-disciplinary conservatism
as one of the major barriers to the usage of ADs, par-
ticularly in the confirmatory phase. This conservatism
depended on: Most importantly, we inferred a complex
multifaceted degree of conservatism, which appears to
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be influenced by many factors. Table 4 summarises sub-
themes inferred to influence conservatism and negative
attitudes towards ADs.
1. Trial phase and nature of research objective(s),
2. Health condition or study population and nature of
intervention under consideration,
3. Rationale put forward and completeness in
description of the proposed AD(s),
4. Type and scope of proposed AD, the availability of
well-established methods for statistical inference, and
perceptions towards that AD by policymakers,
5. Perceived complexities associated with the AD and
impact on implementation, potential introduction of
operational bias during conduct, and interpretation of
the findings, and
6. Underlying familiarity and understanding of the
proposed AD.
Table 4 Inductive themes perceived to be linked to conservatism
Stakeholder Secondary theme associated with conservatism Contributors linked to secondary theme
Cross-disciplinary ▪ Unfamiliarity and lack of understanding
▪ Fear of introducing operational bias
during conduct and compromising the trial
▪ Concern about the robustness of ADs in
decision-making
▪ Fear of making wrong decisions
▪ Concerns about premature early stopping of trials
▪ Concern that the research community may struggle
or be reluctant to accept the findings from an adaptive trial
▪ Contrived general perception by journal editors and
reviewers that early trial stopping is a failure
▪ Impact of early trial stopping on other secondary but
important objectives
▪ Research teams being more comfortable
with traditional fixed designs than ADs
▪ Sticking to what we know best and fear of venturing
into the unknown
▪ Lack of knowledge and experience
▪ Generation effect - more senior trialists being sceptical
of change from what they know best and perceive as standard
▪ Perceived operational and statistical complexities during
planning and implementation
Regulators ▪ Buy in reluctance in confirmatory setting ▪ Lack of understanding of the inferential and regulatory
price to pay by using an AD
▪ Fear of lowering the level of evidence
▪ Fear of making wrong decisions that may taint their
reputation in the future (for instance, approving a drug
that will subsequently be proved to be unsafe or ineffective)
▪ Limited experiences in the assessment and approval of ADs
Statisticians ▪ Negative attitude towards ADs among some
influential statistical community
▪ Generation effect - more senior researchers being sceptical
of change from what they know best and perceive as standard
Private and public funders ▪ Reluctant to fund potential high risk high value
research projects with huge uncertainty
▪ Uncertainty around the actual sample size, duration and
actual cost of the trial
▪ Inadequate description of variable costs, decision-making
criteria and time frames on grant applications (public funders)
▪ Limited commissioning and funding experiences,
especially among public funders
▪ Difficulties in drawing up flexible employment contracts
(public funders)
▪ Limited number of AD grant proposals being submitted
by researchers for consideration (public funders)
▪ Negative attitudes towards ADs among some
public funding panel members
▪ Lack of familiarity
IDMC and TSC members ▪ Perceived negative attitudes towards multiple
examinations of the trial data
▪ Lack of familiarity and understanding
▪ Reluctant to stop trials early unless for safety
reasons
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Most participants stated that there is limited scope
for ADs in confirmatory trials, due to the definitive
nature of research objectives, with direct influence on
policymakers’ decisions to approve new interventions
into clinical practice. Moreover, some participants
strongly advised against conducting too many adapta-
tions in confirmatory trials, citing difficulties in the
interpretation of the findings, which may undermine
trial credibility.
‘… people should be cautious I guess in trying to
do too much and having too many adaptations …
We must still make sure we have that body of
confirmatory evidence, so I think there might be
a place in phase 3 for ADs, but only sort of
minimal adaptations. We should sort of keep
things under control in that particular setting …’
(QL19 Statistician, regulatory assessment
experience)
Insufficient description of proposed ADs, with their
statistical and operational characteristics supported with
evidence (such as from simulation work or established
references) was viewed to influence conservatism to-
wards ADs. This view also reflected the FDA’s regulatory
guidance position, which classified well-understood from
less-understood ADs [8, 43].
We found that the MAMS AD attracted cross-
disciplinary attention, particularly from policymakers,
citing efficiency and value for money in testing mul-
tiple interventions in a single trial, allowing for drop-
ping futile arms, as opposed to conducting multiple
series of independent two arms trials [38, 46].
‘In terms of the multi-arm trials I’m much more
comfortable now with the idea of maybe setting
out, even on a phase 3 trial, with 4 or 5 potential
interventions and dropping the ones that look
least promising’. (QL14 Statistician, no experience)
Lack of knowledge and experience
Cross-disciplinary lack of knowledge and experience
of ADs was perceived as a major barrier. Most partic-
ipants viewed this to be intertwined with insufficient
access to case studies to facilitate practical training,
to raise the awareness of benefits and an understand-
ing of when ADs are appropriate, and learning about
barriers and facilitators to successful implementation.
Certain participants raised concerns about deficiencies
in current training approaches, which they viewed as
more oriented towards statistical methodology rather
than translational practical training. In addition,
weaknesses in some current academic graduate
training curricula, which do not tend to incorporate
ADs as alternative designs, were articulated.
‘… the main challenge … I think it is a bit
broader - is the lack of experience and knowledge
within the bio-statistics community. There is a
lack of understanding of adaptive methods, a lack
of understanding of the opportunities, you know
and a lack of familiarity’. (QL12 Clinical Research
Leader, Trial Methodologist, design and conduct
experience)
A number of participants conveyed a lack of familiarity
and knowledge of alternative ethical and efficient designs
among ethics and scientific review board members,
which may hamper their ability to adequately review
grant proposals. The lack of capacity and competency of
peer reviewers of AD grant proposals in the public sec-
tor was also a perceived barrier. Similar concerns were
also reflected in the United States [11, 12].
Degree of statistical and operational complexity
Amount of work and effort required and marketing of ADs
to key stakeholders
Most participants stated that ADs, in general, require
additional work and effort from a statistical and
operational perspective compared to traditional fixed
sample size designs during planning and implementa-
tion. Consideration of operational feasibility - how
implementation of the AD is going to work in practice -
was viewed to be vital. Operational feasibility encompasses
aspects such as logistics, administration, resources,
primary endpoint relative to the expected recruitment
rate, implications of trial governance processes and collab-
orating sites, and intervention delivery [14]. However, the
level of statistical and operational challenges depends on
the nature of the proposed AD and tends to increase with
its complexity. A number of participants believed that
more time and effort (depending on the type of AD) is
required in marketing the rationale for the proposed AD
to key stakeholders (such as funders, regulators and
clinical collaborators) and in planning, compared to
traditional fixed sample size designs.
Statistical simulation work at the design stage
Some participants mentioned that ADs require more
effort and time (depending on the complexity of the
AD) to conduct adequate simulation work under
various scenarios, and to understand the statistical
properties of the design and its implications on
decision-making [35]. Some of our interviewees men-
tioned the concern about inadequate simulation work
and its consequences on statistical properties and
decision-making. Regulators raised similar concerns
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about a response adaptive randomisation case study,
concerning whether the simulation scenarios covered
the entire domain of the desired sample space to
guarantee control of the type I error (see Additional
file 2, Case Study C). Some participants identified the
need for applied training of statisticians on how to
undertake adequate simulation work of ADs.
Robust data management infrastructure
Some participants viewed data management and related
logistical challenges as potential barriers due to the need
to minimise operational bias in the conduct of ADs and
to provide clean, robust data to inform the adaptation
process. The following considerations were raised:
1. Compatibility of data management infrastructure
with collaborators;
2. Real-time data capturing, cleaning and processing.
An example of a successful multi-centre case study,
which used tablet computers for real time electronic
data capturing in an African-based trial setting was
shared (see Additional file 2, Case Study B);
3. Turnaround time of data management processes to
inform adaptation; and
4. Systems, processes and procedures supported with
audit trails to minimise potential operational bias
encompassing the sort of information that should be
disclosed and to whom, how the information should
be transferred, and firewalls and clarity on who is
doing what.
Confidentiality and implications of ADs on IDMC duties and
responsibilities
The need to maintain confidentiality by the IDMC during
communication and execution of their duties supported
with documentation was viewed as paramount. It was
advised that the training of and discussions with IDMC
members prior to trial commencement regarding the pro-
posed AD; related decision-making criteria; execution of
their duties as guided by formalised documents, such as a
charter [47]; communication protocol; and clarification on
related issues are essential. Some participants stated that
ADs, depending on complexity, may require more effort,
time and expertise for the IDMCs in understanding the
design, its decision rules and execution.
Additional statistical considerations
The availability of in-house statistical expertise supported
with quality control, validated software or user written
statistical codes to execute the AD, and delivery time of
results to inform interim decision-making were some of
the statistical obstacles raised. However, these depend on
the type of proposed ADs. An experienced statistician
shared a case study where they adapted the methods from
another clinical area using a different endpoint to suit their
research question but with additional statistical work and
time commitment (see Additional file 2, Case Study B).
Concerns around trial credibility and integrity
Most participants expressed strong preference for planned
ADs, with decision rules clearly pre-specified at the design
stage: this facilitates adequate understanding of the de-
sign’s statistical properties through simulation and en-
hances proper planning. Most importantly, pre-planning
of ADs is a regulatory necessity to safeguard trial credibil-
ity, integrity and validity, especially in the confirmatory
setting [10, 42]. A resonant view was that ADs are not a
remedy for poor planning, and most participants were
concerned about ad hoc (unplanned) adaptations, which
they viewed with great suspicion, regarding such activity
as cherry-picking and potentially hiding negative findings
to advance the hidden personal agendas of some re-
searchers. Preference for ‘prospectively-planned adapta-
tion’ or the ‘adaptation by design’ concept, particularly in
the confirmatory phase, is reinforced in the literature and
regulatory guidance [8, 9, 35, 43].
Fear of compromising the trial by potential introduc-
tion of bias during its conduct and potential population
drift during adaptation were viewed as major concerns,
which could be due to dissemination of the interim re-
sults [8, 35]. The need for safeguards and firewalls to
minimise leaking of interim results, with clear processes,
procedures and documentation with audit trails was re-
inforced [10, 14]. These shared views are in agreement
with some of the considerations highlighted in the EMA
reflection paper [42] and the FDA guidance document [43].
‘I think it (ADs) will always raise an element of
suspicion if there have been some decisions made
along the way that have been data driven. And the key
thing is just to have all the documentation in place; it
has to be set out precisely in the protocol how it will
be done and you need the right mechanisms in terms
of the monitoring committee or steering committee
makes the decision and make sure you comply with
all the mechanisms. I mean it’s like GCP (Good
Clinical Practice); it’s not enough to do the right
thing, you’ve actually got to be able to prove you’ve
done the right thing… with adaptive trials it’s that
much harder to prove that you’ve done it legitimately.
So you’ve got to be very careful about the process and
got to be able to demonstrate through documentation
that you have followed true process’. (QL14
Statistician, no experience)
Although most participants acknowledged routine
monitoring as part of every trial, some expressed con-
cern about the lack of understanding of the impact of ad
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hoc changes on the statistical properties of the design,
introduction of bias, interpretation and credibility of the
findings [35]. They also highlighted the need for some
minimal flexibility as part of routine monitoring in case
of unexpected events within a planned AD framework.
Anticipation of possible scenarios as much as possible at
the planning stage was viewed as imperative.
Concerns around trial validity
A number of statisticians and regulators expressed anxiety
about the use of appropriate statistical inference following
an AD, arguing that little attention is paid by researchers
to the impact on trial results (estimates of treatment ef-
fects, confidence intervals (CIs) and P-values). However,
they seemed to acknowledge that the awareness regarding
control of the type I error rate has improved. More so,
some participants highlighted the need for adequate trans-
parency in the conduct and reporting of ADs, and opinion
seems divided on whether the current CONSORT guid-
ance is fit for purpose in the case of ADs.
Public sector perspective
Worry about impact of ADs on research staff employment
contracts
Some participants stated that the existing public funding
models for fixed trial designs create financial uncertainty
for research staff employment contracts when trials are
stopped early [13]. Consequently, there is nervousness
among some UK CTU directors to support certain ADs
with options for early stopping. However, some partici-
pants stated that this problem is not unique to ADs be-
cause some fixed designed trials are stopped early, mainly
due to poor recruitment [48, 49]. In contrast, they also
stated that design flexibility is somewhat inevitable, due to
a paradigm shift by some UK public funders towards risk
assessment within an internal pilot framework, with asso-
ciated staggered research contracts. In addition to the UK
CTU reputation and experience, some participants viewed
that concerns about the impact of the funding model on
staff contracts depends on factors such as the following:
1. Type of AD proposed - some ADs such as SSR and
MAMS are less likely to be affected.
2. Size of the research group and trial portfolio - large
UK CTUs can more easily reassign staff to other
trials in the pipeline when an AD is stopped early.
3. Remit of the public funder - some have more flexible
funding models than others.
‘… Because of the size of the trials unit there are
many trials that are taking place so we look very
closely at people’s contracts and what studies are
taking place, it’s not just based on 1 study. We have a
lot of different trials at the trials unit so the
infrastructure allows for -if the trial stops early then
they would be able to work on another trial. So it is
not driven by the fact that the contracts or by
whether or not it would stop early on this particular
trial because of the other trials taking place requiring
statistical, trial management, data management
support’. (QL27 Statistician, design and conduct)
Many participants acknowledged the need for public
funders to draw up standardised, flexible funding agree-
ments compatible with key research partners: UK CTUs,
Universities, sites and UK CRN [50]. Some suggested
this could be achieved through modification of the
current staggered research contracts employed for stud-
ies with internal pilots.
Lack of capacity within UK CTUs and time limitation
Most participants stated that there is a lack of expertise
and capacity, particularly a dearth of statisticians and pro-
posal developers with knowledge to support complex
ADs. However, they acknowledged that capacity and ex-
pertise varies across UK CTUs. The majority of partici-
pants mentioned that they have limited time to support
design work of complex ADs - citing the extra work re-
quired against pressure to deliver on competing priorities
based on simpler, traditional, fixed sample size designs.
‘One is just the lack of expertise within the unit, so it is
easier when you are very busy to put forward a design
you know rather than one you don’t. It is also easier
because if you put forward a design that does not look
the same to clinicians who expect straightforward
designs you have to be very confident in that design to
be able to convince them to some extent’. (QL9 CTU
Director, Statistician, design experience)
Lack of bridge funding for UK CTUs to support planning
Some UK CTU directors voiced concern about the lack of
a business case [13] - citing the amount of time required
to support the design of complex ADs, which is unpaid
for, betting on uncertain future success of grant applica-
tions. Similar concerns have been raised in the US publicly
funded setting [11, 12]. UK CTU directors called for fund-
ing opportunities in the form of developmental grants to
support adequate design work of complex ADs, condi-
tional on meeting research and funding priorities.
‘I think for some of the really complex ADs it would be
good if there was availability to go for some small trial
development grants so that you could say ‘look this is a
convincing clinical question, we think it should be
approximately this sort of design but actually we need
£20,000 or whatever to properly work it up and design
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it’ and that type of trial development grant I think
would help unlock some of that’. (QL09 CTU Director,
Statistician, design experience)
Although this was acknowledged, a funder expressed a
contrasting view; citing that in the UK, bridge funding is
partly addressed through the NIHR infrastructure sup-
port funding accessible to over 25 accredited UK CTUs
on a rolling contract basis [51]. However, UK CTU
directors’ views appear to suggest that this funding is
insufficient, and there is high risk attached to supporting
the design work of complex ADs. Funders suggested that
researchers may need to consider applying for small
grants within the remit of other NIHR funding streams
to support developmental work of ADs.
‘Typically for complex ADs then you have to do quite
a lot of modelling -that could take 12 or 18 months.
Ideally, there should be grants to cover that early
development work. Yes, I have sympathy to the idea
that there needs to be additional funding but on the
other hand I suppose all work that CTUs do prior to
a trial application is done at risk. When I was CTU
director, typically you are talking about 2 years work
before you applied to do a definitive trial. I could say
there ought to be more grants to help with all of that
and the reality is that we in [organisation] in a sense
do pay that upfront because we have a scheme
whereby we support CTUs, we give them £250,000
per year if you like, like a front loaded loan, which
they use to buy core staff in order to develop new
projects. So in a way I think we are doing it already’.
(QL25 Chair - Public Funder)
Limitations of the grant application process
In the case of complex ADs, some participants suggested
the need to increase the proposal development time prior
to submission deadlines to give researchers adequate plan-
ning time, particularly for commissioned calls. Some
authors suggested a minimum of 3 months for design and
planning for ADs [14]. Moreover, a slight modification to
the grant application form depending on the funding re-
mit was suggested, to give more space for researchers to
describe the rationale, design and its properties, decision
scenarios and variable costs adequately.
‘From a practical point of view when you are
designing adaptive trials there is more work involved
for the application in planning the trial and working
out the timelines … you have to do it for a number of
different scenarios. So the work involved in that is
more from the trialist and statistician’s point of view,
the statistician has to do various modelling and look
at different scenarios and we have to do all of the
different planning and you are usually on a fairly tight
deadline for applications because of the way that
NIHR funding works so if you only have 6 weeks to
work with the team, trying to fit in time to do lots of
different scenarios can be quite tricky and can make it
more difficult’. (QL01 CTU Deputy Director, Proposal
Developer, design experience)
‘There is not an existing section in grant submissions
that says ‘if you are doing an adaptive trial design
please provide the following information’, so I just
don’t know that it’s well organised yet and that could
be a good thing or a bad thing …’ (QL22 Chief
Investigator, design experience)
Discussion
Contributions of this study and implications for practice
and future research
We found the following cross-sector perceived barriers to
the use of ADs in confirmatory trials among the stake-
holders we interviewed:
1. Lack of practical knowledge and applied training
coupled with insufficient access to case studies to
facilitate practical learning.
2. Time constraints to support planning relative to
other competing priorities based on traditional
designs.
3. Lack of awareness of opportunities about when ADs
are appropriate in conjunction with the lack of
understanding of their acceptable scope in
confirmatory trials.
4. Statistical and operational complexities during
planning and implementation of ADs.
5. A cross-disciplinary degree of conservatism influ-
enced by various factors.
Specific to the public sector the barriers included lack
of bridge funding accessible to UK CTUs to support the
design work of complex Ads, difficulties in marketing
ADs to collaborators, anxiety about the impact of early
trial stopping on full-time researcher employment con-
tracts and lack of capacity to support ADs. Some of
these barriers have already been previously reported
[2, 5, 11, 13, 14].
Practical education tailored to trialists is paramount to
address the lack of practical knowledge. Activities such as
educational seminars or webinars and practice-oriented
workshops can facilitate translational knowledge sharing.
The content of such activities should cover the practical,
statistical and logistical issues that need to be addressed in
planning and conduct of adaptive trials with the aid of
case studies where possible.
Dimairo et al. Trials  (2015) 16:430 Page 12 of 16
We strongly encourage accessible publication of ‘suc-
cessful’ and ‘unsuccessful’ case studies of ADs previously
undertaken, addressing aspects beyond the primary re-
sults, such as practical barriers and facilitators, which will
complement the educational resources. These should
include positive and negative lessons learnt to help the
design and conduct of future adaptive trials. Adequate
reporting and indexing of these AD-related publications
of case studies is important. We are now witnessing such
publications in the literature [52–56].
The establishment of small design developmental grants
accessible to UK CTUs could encourage trialists wishing
to undertake time-consuming and complex ADs, which
are efficient to address research questions. Such small
grants could be a collaborative initiative among public
funders such as the NIHR and MRC. There is an issue
that needs to be addressed of funding for statistical AD
design work being granted before the merits of the scien-
tific clinical question have been fully addressed. This may
entail trialists going through a multi-stage grant applica-
tion process. An initial ‘Outline’ stage could encompass
putting forward the research question, justifying its im-
portance, design rationale, explaining the gap in the
design requiring further work, and time and resources
required to undertake such work. Trialists could then
be sign-posted to apply for small grants to develop
the design conditional on the ‘Outline’ proposal meet-
ing research and funding priorities. Further funding
of the main trial could then be available conditionally,
subject to the outcome of the design work. In
addition, there should be mandatory open access pub-
lication of the initial stage design-related outputs such
as statistical software or implementation codes to help
the design of future similar studies.
We found evidence of a complex, multifaceted cross-
disciplinary degree of conservatism, which appears to
influence perceptions and attitudes towards use and ac-
ceptability of ADs among our study participants. We un-
covered some of the factors influencing this conservatism,
thereby aiding our understanding to address barriers to
use and acceptability of ADs. For instance, concerns that
the research community, clinical community and policy-
makers may struggle to accept findings from ADs to influ-
ence policy underscores the strong need for methodological
assurances and effective communication regarding robust-
ness in decision-making. We believe adequate description
of the proposed AD, with clear rationale, scope, and its
operational and statistical properties supported with
tangible simulation evidence where necessary, may alleviate
some cited concerns [2, 7, 11, 36]. This should include the
appropriateness of the proposed AD to address the research
question(s). Such description must also encompass the use
and adequate reporting of appropriate, established statis-
tical methods to control type 1 error and power and to
obtain unbiased or bias-adjusted results (estimates of treat-
ment effects, CIs and P values).
The use of retrospectively planned case studies aided
with simulation work may help illustrate lost opportun-
ities and provide assurance of the robustness of ADs in
decision-making. This may also facilitate practical learning
and highlight some pitfalls during the implementation of
ADs. In addition, a review of undertaken ADs published
in ‘high impact’ peer-reviewed journals and their publicity
may help to improve acceptability of ADs in research to
change clinical practice. Reassurance of the rigour in the
science and conduct of ADs enhanced through transpar-
ent, adequate and accessible trial reports is paramount.
Such accessible related trial materials include protocols
(and amendments), simulation protocols and reports,
open and closed IDMC minutes and interim results
reports. Consumers of research findings should be able to
make informed judgements about the quality of the AD in
front of them. This can only be achieved through adequate
transparent reporting that has been improved by the
advent of CONSORT statements [57, 58]. Recent studies
have suggested some modifications to the CONSORT
guidance to accommodate ADs [12, 59], without, however,
underpinning evidence regarding the state of reporting of
ADs. We propose cross-disciplinary and cross-sector
discussions to draw recommendations for a modified
adaptive CONSORT statement.
We also recommend some form of standardised, con-
sensus guidance toolkit tailored for the public sector
(where interventions are so variable) similar to the guid-
ance for the evaluation of complex interventions [60] that
will address appropriate scope, benefits, statistical and
practical considerations for successful implementation of
ADs in confirmatory trials. This should be carefully
crafted so as not to stifle design innovation. In addition,
we propose the development of a troubleshooting toolkit
tailored for trialists on important general and design-
specific questions they should ask themselves when con-
sidering ADs at the planning stage. In our opinion, poor
communication and dissemination deficiencies of AD
methods to researchers are important perceived barriers,
which require addressing. A generalised complexity mes-
sage - ‘ADs are complex to design, implement and analyse’
- could act as a barrier, by deterring researchers from
implementing even simple ADs because the level of com-
plexity varies considerably across types of ADs. Hence, we
believe there is scope for a toolkit addressing practical and
statistical issues specific to particular forms of ADs, rather
than the most common generic qualitative statements.
We believe too much generalisation of AD-related issues
is becoming a syndrome and a communication barrier
scaring off some researchers.
We advocate for ADs to be considered alternative trial
designs in the ‘toolbox’ of trialists and incorporated as part
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of MSc academic training curricula in Universities - tar-
geting aspiring trialists and not just statisticians. It is also
vital to raise awareness regarding the acceptable scope of
Ads, when appropriate, among UK CTU trialists. We
encourage collaboration among UK CTUs and industry
organisations and the creation of a knowledge-sharing
platform on AD-related issues to facilitate problem solving
and learning from pacesetters. We support initiatives by
UK public funders such as the NIHR and MRC on AD-
related capacity building. We hope these efforts will
enhance the capacity of experts with practical knowledge
to help UK CTUs wishing to undertake efficient, but time
consuming and complex ADs, when appropriate. These
experts should also be available to undertake scientific
peer-review of AD-related grant applications.
We support initiatives by public funders to communi-
cate their receptiveness towards appropriate use of effi-
cient designs such as ADs. We encourage more effort
through outreach events to communicate this shift in pos-
ition to trialists and launching of related funding research
opportunities. In addition, we encourage knowledge and
experience sharing among public funders to facilitate
problem solving on AD-related issues, such as drawing up
flexible contractual agreements suited to ADs. Refresher
training of public funding panels and board members
prior to their grants review meetings may improve their
awareness on AD-related issues. More so, it is important
for trialists to describe aspects of the proposed AD and
related decision-making scenarios adequately in grant
applications in order to help public funders to make in-
formed decisions.
Strengths and limitations of the study
The main strength of this study is that we have built upon
previous research by incorporating interviews of key
stakeholders and maximised sampling variation to capture
perceptions and experiences that are more diverse to
inform subsequent surveys to be reported elsewhere. This
enhanced our robust exploration of barriers and related
facilitators to the uptake of ADs. We also used an add-
itional experienced qualitative researcher (JB) to validate
consistency in annotation and coding of 7(26 %) of the
transcripts, which is recommended as good practice in
some qualitative research good practice checklists [34]. In
addition, mapping of themes was discussed independently
with experienced qualitative researchers (JB and Alicia
O’Cathain).
One of the study limitations is the poor participation
by health economists, which limited the exploration of
AD-related issues among this stakeholder group. Non-
participation could be due to a lack of basic understanding
of ADs and their implications for health economic evalu-
ation when trials are stopped early, and to some extent,
health economists may feel on the periphery of clinical
trial design. Thus, there is need for research to understand
the implications of ADs on health economic evaluation.
Finally, our study participants were predominantly from
the UK public-funded setting - thus generalisation to
other settings, particularly in relation to organisational
barriers may be limited.
Conclusions
There are still considerable, multifaceted individual and
organisational barriers perceived to be hampering the
appropriate use of ADs in publicly funded confirmatory
trials Nevertheless, widespread interest and UK public
funders’ perceived positive changes in attitudes and
receptiveness towards ADs when appropriate are
supportive, and a platform for the future use of ADs in
the UK public sector. Our findings have been used to
inform the design of follow-up surveys to be reported
elsewhere, aiming to generalise these findings, rank bar-
riers with respect to importance for prioritisation and to
contrast themes on barriers between stakeholders based
in private and public settings.
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